BioLife Solutions, Inc. (BLFS)
After hours:
| Previous close | 17.48 |
| Open | 17.79 |
| Bid | 18.13 x 200 |
| Ask | 18.20 x 200 |
| Day's range | 17.34 - 18.32 |
| 52-week range | 8.92 - 24.50 |
| Volume | |
| Avg. volume | 387,414 |
| Market cap | 822.648M |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business
- PR Newswire
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").
- PR Newswire
BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.
